EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities DOI Open Access
Lisa Toracchio, Marianna Carrabotta, Caterina Mancarella

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12191 - 12191

Published: Nov. 13, 2024

Erythropoietin-producing hepatocellular A2 (EphA2) is a member of the Eph tyrosine kinase receptor family that has been linked to various biological processes. In tumors, EphA2 overexpression associated with noncanonical pathway activation, tumor progression, and poor prognosis, which emphasized its importance as marker malignancy. Studies on numerous cancer models have highlighted EphA2’s dual often contradictory action, can be attributed EphA2′s interactions involving multiple pathways different ligands, well heterogeneity microenvironment. this review, we summarize main mechanisms underlying dysregulation in cancer, highlighting molecular complexity. Then, analyze therapies developed over time counteract action. We discuss limitations described approaches, emphasizing fact goal new options high specificity without losing therapeutic efficacy. For reason, immunotherapy or emerging field targeted protein degradation proteolysis-targeting chimeras (PROTACs) may represent promising solution based deeper understanding sustaining oncogenic activity.

Language: Английский

EphA2 in Cancer: Molecular Complexity and Therapeutic Opportunities DOI Open Access
Lisa Toracchio, Marianna Carrabotta, Caterina Mancarella

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12191 - 12191

Published: Nov. 13, 2024

Erythropoietin-producing hepatocellular A2 (EphA2) is a member of the Eph tyrosine kinase receptor family that has been linked to various biological processes. In tumors, EphA2 overexpression associated with noncanonical pathway activation, tumor progression, and poor prognosis, which emphasized its importance as marker malignancy. Studies on numerous cancer models have highlighted EphA2’s dual often contradictory action, can be attributed EphA2′s interactions involving multiple pathways different ligands, well heterogeneity microenvironment. this review, we summarize main mechanisms underlying dysregulation in cancer, highlighting molecular complexity. Then, analyze therapies developed over time counteract action. We discuss limitations described approaches, emphasizing fact goal new options high specificity without losing therapeutic efficacy. For reason, immunotherapy or emerging field targeted protein degradation proteolysis-targeting chimeras (PROTACs) may represent promising solution based deeper understanding sustaining oncogenic activity.

Language: Английский

Citations

2